远程医疗的初创公司这么多，强生为什么大手笔投资这一家？
在新冠疫情期间，远程医疗行业日益兴起，投资者坚信即使在疫情结束之后，这种热度也会持续下去。
最近的例子是一家初创公司Thirty Madison。该公司提供治疗脱发、偏头痛和胃酸反流的在线医疗平台。该公司在14日宣布，从医学用品巨头强生（Johnson & Johnson）旗下的风险投资部门以及Polaris Partners（领投本轮融资）、Maveron和Northzone等投资公司融资4,700万美元。
这是强生旗下的风投部门在远程医疗领域的一次大手笔投资。强生北美西部、澳大利亚和新西兰投资负责人斯泰西•费尔德在一封电子邮件中表示，投资Thirty Madison“符合我们的整体策略，即提供新型医疗产品和解决方案，解决人们的迫切需求。”
她补充说，该笔投资“体现了一个广泛趋势，即人们正在寻求慢性医疗的个性化方案。”此外，她表示：“新冠疫情加快了医疗护理方式的转变，例如通过远程医疗。”她认为这种转变并不是一时的热潮。
事实上，在新冠疫情期间，医生和患者都要尽量避免接触病毒，因此远程医疗服务大受欢迎。
提供远程医疗服务的公司，例如2017年成立的Thirty Madison，面临着Teledoc、MDLive和American Well等公司的激烈竞争。许多公司经营远程医疗服务的时间更长，资金实力更雄厚。
Thirty Madison公司CEO史蒂文•高腾特格说，该初创公司正在尝试以个别慢性疾病为业务重点，而不是提供更多通用服务，例如虚拟就诊等，希望以此作为区别于竞争对手的特色。该公司的服务支持患者通过特定疾病的门户网站寻医问药，安排虚拟就诊和购买药品等。
Polaris Partners主理合伙人兼Thirty Madison新任董事会成员埃米•舒尔曼说，在线医疗服务早在新冠疫情之前已经开始飞速发展，因为年轻人生活中的很多事情都在网上解决。
舒尔曼曾在制药业巨头辉瑞（Pfizer）经营消费者业务。她说：“有一代人将在线上完成各种事情，这在我们这一代人看来是不可思议的。”
Thirty Madison的收入来自通过网站销售药品和治疗方法的所得。
高腾特格承认，患者可能不选择公司的医疗平台，改为从其他渠道购买药品。但他说公司提供的一站式医疗服务，更能吸引患者。随着许多人因为新冠疫情首次尝试在线医疗服务，他希望他的初创公司的服务能够脱颖而出。
高腾特格：“过去三年，我们一直在为这个时刻做准备，而且我们能够抓住这次良机。”
他补充说，目前没有计划授权公司的技术，支持其他公司创建医疗门户网站。但他对未来提供这种授权保持开放的心态。
Thirty Madison自创立至今共融资7,000万美元。对于上一轮融资的估值，公司拒绝发表评论。（财富中文网）
译者：Biz
在新冠疫情期间，远程医疗行业日益兴起，投资者坚信即使在疫情结束之后，这种热度也会持续下去。
最近的例子是一家初创公司Thirty Madison。该公司提供治疗脱发、偏头痛和胃酸反流的在线医疗平台。该公司在14日宣布，从医学用品巨头强生（Johnson & Johnson）旗下的风险投资部门以及Polaris Partners（领投本轮融资）、Maveron和Northzone等投资公司融资4,700万美元。
这是强生旗下的风投部门在远程医疗领域的一次大手笔投资。强生北美西部、澳大利亚和新西兰投资负责人斯泰西•费尔德在一封电子邮件中表示，投资Thirty Madison“符合我们的整体策略，即提供新型医疗产品和解决方案，解决人们的迫切需求。”
她补充说，该笔投资“体现了一个广泛趋势，即人们正在寻求慢性医疗的个性化方案。”此外，她表示：“新冠疫情加快了医疗护理方式的转变，例如通过远程医疗。”她认为这种转变并不是一时的热潮。
事实上，在新冠疫情期间，医生和患者都要尽量避免接触病毒，因此远程医疗服务大受欢迎。
提供远程医疗服务的公司，例如2017年成立的Thirty Madison，面临着Teledoc、MDLive和American Well等公司的激烈竞争。许多公司经营远程医疗服务的时间更长，资金实力更雄厚。
Thirty Madison公司CEO史蒂文•高腾特格说，该初创公司正在尝试以个别慢性疾病为业务重点，而不是提供更多通用服务，例如虚拟就诊等，希望以此作为区别于竞争对手的特色。该公司的服务支持患者通过特定疾病的门户网站寻医问药，安排虚拟就诊和购买药品等。
Polaris Partners主理合伙人兼Thirty Madison新任董事会成员埃米•舒尔曼说，在线医疗服务早在新冠疫情之前已经开始飞速发展，因为年轻人生活中的很多事情都在网上解决。
舒尔曼曾在制药业巨头辉瑞（Pfizer）经营消费者业务。她说：“有一代人将在线上完成各种事情，这在我们这一代人看来是不可思议的。”
Thirty Madison的收入来自通过网站销售药品和治疗方法的所得。
高腾特格承认，患者可能不选择公司的医疗平台，改为从其他渠道购买药品。但他说公司提供的一站式医疗服务，更能吸引患者。随着许多人因为新冠疫情首次尝试在线医疗服务，他希望他的初创公司的服务能够脱颖而出。
高腾特格：“过去三年，我们一直在为这个时刻做准备，而且我们能够抓住这次良机。”
他补充说，目前没有计划授权公司的技术，支持其他公司创建医疗门户网站。但他对未来提供这种授权保持开放的心态。
Thirty Madison自创立至今共融资7,000万美元。对于上一轮融资的估值，公司拒绝发表评论。（财富中文网）
译者：Biz
Investors are betting that telemedicine's increased popularity during the coronavirus pandemic will continue after the outbreak is over.
The latest example is Thirty Madison, a startup that offers online health portals for treatment of hair loss, migraines, and acid reflux. It said on Thursday that it had raised $47 million from the venture capital arm of health product giant Johnson & Johnson along with investment firms Polaris Partners (which led the round), Maveron, and Northzone.
The investment marks a major investment in telemedicine by Johnson & Johnson's venture capital arm. Stacy Feld, the Johnson & Johnson investment head of west North America, Australia, and New Zealand, said in an email that the investment into Thirty Madison "aligns to our overall strategy, which is to bring new health care products and solutions to the people who need them most."
She added that the investment "reflects the broader trend of individuals seeking personalized, on-demand solutions for their chronic health care needs." In addition, she said that "COVID-19 has accelerated certain changes in the way health care is delivered, for example, via telemedicine" and that she believes it's not a fad.
Indeed, telehealth services are gaining a huge following during the coronavirus pandemic as both doctors and patients try to limit their exposure to the virus.
Companies offering telehealth services like Thirty Madison, founded in 2017, face a huge amount of competition from services like Teledoc, MDLive, and American Well. Many companies involved have much longer track records and deeper pockets.
Thirty Madison CEO Steven Gutentag said the startup is trying to differentiate itself from rivals by focusing on specific chronic disorders rather than offering more general services, like virtual doctor visits. Its service connects patients through portals for specific ailments with physicians, schedules virtual appointments, and orders their medications.
Amy Schulman, managing partner of Polaris Partners and a new Thirty Madison board member, said that online health services were already gaining momentum before COVID-19 because young adults are used to conducting much of their lives online.
“There’s a generation of people who will do things online that were unthinkable to my generation,” said Schulman, who once ran the consumer business for pharmaceutical giant Pfizer.
Thirty Madison makes money by selling medications and treatments through the site.
Gutentag acknowledged that patients could get their medications from elsewhere rather than his company's health portals. But he said that one-stop for health care services makes its sites more appealing to use. He's hoping that with many people trying online health care services for the first time because of the coronavirus, his startup's services will stand out.
"We've been building toward this moment for the last three years and we’re in a position to capitalize on it," said Gutentag.
He added that there are no current plans to license the startup’s technology so that others can create their own health portals. But he left the door open to doing so in the future.
Overall, Thirty Madison has raised a total of $70 million since its founding. It declined to comment about its valuation in its latest funding round.
